HealthRecordCommunity
FHIR🌏 Taiwan🏛 Economic Development Foundation; Ministry of Health and WelfareEnriched

Taiwan's Bio Industry Gains Momentum with NT$10 Billion Fund Support

國發基金百億助攻,台灣生醫組國家隊迎商機

August 24, 2026Economic Development Foundation; Ministry of Health and Welfare

Summary

The Taiwanese biotech and pharmaceutical industry is advancing through government funding and academia-industry collaboration. The Economic Development Foundation has passed the 'Investment in Taiwan's Biotech Industry Implementation Plan,' committing NT$10 billion over 10 years to build a national smart bio team. Furthermore, the Ministry of Health and Welfare is promoting FHIR adoption, aiming for nationwide medical center data connectivity by year-end.

Details

Taiwan's biotech sector is undergoing significant transformation, driven by massive government support and technical standardization efforts. Based on the 'Investment in Taiwan's Biotech Industry Implementation Plan,' the Economic Development Foundation plans to allocate NT$10 billion over the next decade. This initiative aims not only to provide funding but also to consolidate resources across various governmental departments to build a national smart bio team. On the healthcare IT front, the Ministry of Health and Welfare is actively promoting the adoption of FHIR (Fast Healthcare Interoperability Resources), an international standard. The plan involves completing data connectivity for medical records across all national medical centers by year-end. This development is crucial for establishing a robust data linkage foundation necessary for future AI learning platforms and advanced regional healthcare services. Specific R&D examples include a collaboration between Abang Biotech and the Tokyo University Veterinary Science Laboratory, aiming to expand the human clinical indications for ABT-301. Additionally, the approval by the Ministry of Health and Welfare of a new indication (Primary Myelofibrosis) for PharmaCare's drug BESREMi marks Taiwan as an indicator case of its pharmaceuticals gaining international recognition. Market projections suggest that global healthcare expenditure is expected to reach $15 trillion by 2030, accounting for about 12.1% of global GDP. Facing this rising global demand, Taiwan leverages its dual advantage in Bio and ICT, aiming to address unmet medical needs through deepened international cooperation utilizing national health insurance data and human biological databases.

📰
Read Original Article
cmnews.com.tw
→

Original content copyright by respective publishers